Evolving strategies and application of proteins and peptide therapeutics in cancer treatment

Mukherjee, Anirban Goutam; Wanjari, Uddesh Ramesh; Gopalakrishnan, Abilash Valsala; Bradu, Pragya; Biswas, Antara; Ganesan, Raja; Renu, Kaviyarasi; Dey, Abhijit; Vellingiri, Balachandar; Allali, Achraf El; Alsamman, Alsamman M.; Zayed, Hatem; Doss, C. George Priya

doi:10.1016/j.biopha.2023.114832

Cited by 12 publications

(2 citation statements)

References 375 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditional vaccines, such as live-attenuated, inactivated, subunit, and conjugate vaccines [ 37 – 39 ], are not ideally suited for cancer vaccination due to their lack of specificity in distinguishing between normal host cells and cancerous host cells [ 40 ]. In contrast, peptide-based vaccines deliver peptide epitopes from shared tumor-associated antigens (TAAs), specifically targeting histocompatibility complex class I restricted peptides to activate CD8 + T cells against cancer [ 41 , 42 ]. This specificity has positioned peptide-based vaccines as highly promising compared to classical vaccines [ 43 ].…”

Section: Introductionmentioning

confidence: 99%

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role in preventing illness by preparing the body's adaptive and innate immune responses to combat diseases. As our understanding of malignancies and their connection to the immune system improves, there has been a growing interest in priming the immune system to fight malignancies more effectively and comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which has been shown to potentiate immune responses as vaccines and/or adjuvants. In this review, we comprehensively summarized the immunological mechanisms of cancer vaccines while focusing specifically on the recent applications of various types of nanoparticles in the field of cancer immunotherapy. By exploring these recent breakthroughs, we hope to identify significant challenges and obstacles in making nanoparticle-based vaccines and adjuvants feasible for clinical application. This review serves to assess recent breakthroughs in nanoparticle-based cancer vaccinations and shed light on their prospects and potential barriers. By doing so, we aim to inspire future immunotherapies for cancer that harness the potential of nanotechnology to deliver more effective and targeted treatments. Graphical abstract

show abstract

Section: Introductionmentioning

confidence: 99%

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Proteinbased drugs encompass therapeutic agents consisting of proteins or peptides engineered to interact with specic targets within the body for the treatment or management of diseases. [1][2][3] The human proteome contains an estimated 20 000 proteins. 4 Proteins are highly versatile biomolecules playing crucial roles in various biological processes.…”

Section: Introductionmentioning

confidence: 99%